Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer.

Radiology and Oncology
Tanja MarinkoCvetka Bilban-Jakopin

Abstract

The purpose of the study was to find out whether there is a difference in the early parameters of cardiotoxicity (left ventricular ejection fraction [LVEF] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) between the two groups of patients: the patients treated for left breast cancer (left breast cancer group) and those treated for the right breast cancer (right breast cancer group), after the treatment had been completed. The study included 175 consecutive patients with human epidermal growth factor receptor-2 (HER2) positive early breast cancer, treated concurrently with trastuzumab and radiotherapy (RT), between June 2005 and December 2010. Echocardiography with LVEF measurement was performed before adjuvant RT (LVEF0) and after the completed treatment (LVEF1,). After the treatment NT-proBNP measurement was done as well. The difference (Δ) between LVEF0 and LVEF1 was analysed (Δ LVEF = LVEF0 - LVEF1) and compared between the two groups. There were 84 patients in the left and 91 in the right breast cancer group. Median observation time was 57 (37-71) months. Mean Δ LVEF (%) was -1.786% in the left and -2.607% in the right breast cancer group (p = 0.562, CI: -2.004 to 3.648). Median NT-proBNP were 111.0 ng/l in the l...Continue Reading

References

Sep 19, 2002·Cancer·Deborah L Keefe
Jan 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A Perez, Richard Rodeheffer
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriFrancisco J Esteva
Mar 8, 2007·Journal of the National Cancer Institute·Maartje J HooningFlora E van Leeuwen
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S Ewer, Elizabeth Tan-Chiu
May 16, 2008·The New England Journal of Medicine·Björn ZetheliusJohan Arnlöv
Jul 7, 2012·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Stephen Parker, Andrew Leggett
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Ana Catarina PintoMartine Piccart-Gebhart
Jul 6, 2014·Radiology and Oncology·Tanja MarinkoCvetka Bilban-Jakopin
Dec 2, 2014·Radiology and Oncology·Erika MatosCvetka Grasic Kuhar
Nov 7, 2016·Current Problems in Cancer·Aju Mathew, Edward H Romond

❮ Previous
Next ❯

Citations

Mar 7, 2019·Radiology and Oncology·Tanja Marinko
Jul 29, 2019·Current Cardiology Reports·Natalie Szpakowski, Milind Y Desai
Oct 23, 2019·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Sep 13, 2020·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Jan 6, 2022·International Journal of Radiation Oncology, Biology, Physics·Bachir BachirYoussef H Zeidan

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection

Clinical Trials Mentioned

NCT01572883

Software Mentioned

PASS
Medicview
Intermedical
R

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.